ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.

By M. Ranson, L. Hammond, D. Ferry, M. Kris, A. Tullo, P. Murray, Vincent A. Miller, S. Averbuch, J. Ochs, C. Morris and 3 more. Journal of Clinical Oncology, 2002

788 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/7be248b64576ef1eefe7a0e8e802ca1b6ecae54b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. William Pao
2. Jeremy N. Rich
3. Vincent A. Miller
4. M. Kris
5. E. Scholar
6. A. Arora

In Pulmonary and Respiratory Medicine

1. William Pao
2. Vincent A. Miller
3. M. Kris
4. Gregory Riely
5. Adi F. Gazdar
6. B. Hughes
7. B. Chan

Citations in the corpus

• Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. (2005, background): “The rash seems to be dosedependent [4, 11, 12, 14 , 17] and is seen in more than 50% up to 100% of patients (Table 1). Further studies are ongoing to understand this dose relationship better.”
• Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. (2004, background): “Four phase I studies have shown that gefitinib is generally well tolerated, with evidence of antitumor activity in a range of tumors including NSCLC [5-8].”
• Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. (2004, methodology): “Three phase I trials have been reported [3-5], and in two of these major objective responses were observed in patients with NSCLC refractory to multiple From the Thoracic Oncology Service,”
• Role of Tyrosine Kinase Inhibitors in Cancer Therapy (2005, background): “Headache, mucositis, hyperbilirubinemia, neutropenia, and anemia have also been reported (Ranson et al., 2002; Ranson, 2004).”
• Phase II trial of gefitinib in recurrent glioblastoma. (2004, background): “As expected, the most common toxicities were rash and diarrhea [9-11,26].”